{"id":55951,"date":"2024-02-07T05:47:17","date_gmt":"2024-02-07T05:47:17","guid":{"rendered":"https:\/\/medsname.com\/busiron\/"},"modified":"2026-04-30T10:24:42","modified_gmt":"2026-04-30T10:24:42","slug":"busiron","status":"publish","type":"product","link":"https:\/\/medsbase.com\/nl\/busiron\/","title":{"rendered":"Busiron"},"content":{"rendered":"

<\/p>\n

\n

\u26a1 Snel antwoord<\/h3>\n

Busiron (Buspirone 5 \/ 10 mg) is a 5-HT1A partial agonist for generalised anxiety disorder. Non-sedating, non-addictive, no abuse potential \u2014 but slow onset (3\u20136 weeks). Useful when benzodiazepines are inappropriate.<\/p>\n<\/div>\n

\nWat u krijgt bij MedsBase:<\/strong> WHO-GMP gecertificeerde fabrikant \u00b7 Discrete verpakking \u00b7 Wereldwijde verzending \u00b7 1.400+ geverifieerde klantbeoordelingen<\/a>\n<\/div>\n

\ud83d\udce6 Elke bestelling is gedekt door onze Reshipment Assurance Policy<\/strong><\/a> \u2014 als uw pakket niet binnen 20 werkdagen arriveert, sturen wij het opnieuw.<\/p>\n

Waarom bestellen bij MedsBase<\/h3>\n

Busiron at MedsBase is supplied directly from a WHO-GMP certified manufacturer in plain, discreet packaging. Every order is covered by our Reshipment Assurance Policy<\/a> \u2014 20 werkdagen levertermijn of wij sturen kosteloos opnieuw \u2014 en komt in aanmerking voor ons klantenloyaliteitsprogramma<\/a>. Wereldwijde verzending is beschikbaar naar de meeste bestemmingen.<\/p>\n

What Busiron is and how it works<\/h2>\n

Busiron is a 5 \/ 10 mg buspirone tablet supplied by Intas. Buspirone is a partial agonist at 5-HT1A serotonin receptors and a weak D2 antagonist. The 5-HT1A action reduces anxiety over weeks of dosing; the absence of GABA-A interaction explains why buspirone produces neither sedation, nor amnesia, nor dependence \u2014 distinguishing it sharply from benzodiazepines.<\/p>\n

\nSlow onset is intrinsic \u2014 not failure<\/strong><\/p>\n

Buspirone takes 3\u20136 weeks to reach full anxiolytic effect. It does not work as a PRN agent and does not produce immediate calming. Patients who expect benzodiazepine-like relief in the first week will conclude buspirone “doesn’t work” and stop. Set the expectation up front.<\/p>\n<\/div>\n

Indicaties en dosering<\/h2>\n\n\n\n\n\n\n\n
Indicatie<\/th>\nStartdosering<\/th>\nStreefdosering<\/th>\nMaximaal<\/th>\n<\/tr>\n<\/thead>\n
Generalised anxiety disorder<\/td>\n5 mg BID\u2013TID<\/td>\n20\u201330 mg\/day in 2\u20133 doses<\/td>\n60 mg<\/td>\n<\/tr>\n
SSRI sexual dysfunction (off-label)<\/td>\n10 mg BID<\/td>\n20 mg BID<\/td>\n\u2014<\/td>\n<\/tr>\n
Older adults<\/td>\n5 mg BID<\/td>\n15\u201320 mg\/day<\/td>\n\u2014<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

Take consistently with or without food (food reduces variability). Avoid grapefruit juice (CYP3A4 inhibition).<\/p>\n

Belangrijke veiligheidsoverwegingen<\/h2>\n
\nCYP3A4 substrate<\/strong><\/p>\n

Buspirone is heavily CYP3A4-metabolised. Strong inhibitors (clarithromycin, itraconazole, ketoconazole, ritonavir, grapefruit juice) raise levels 5\u201310\u00d7 \u2014 start at 2.5 mg BID. Strong inducers (rifampicin, carbamazepine, phenytoin, St John’s wort) reduce levels and may abolish efficacy.<\/p>\n<\/div>\n

\nMAO-remmers<\/strong><\/p>\n

14-day washout each direction; concurrent use risks hypertensive crisis.<\/p>\n<\/div>\n

\nNo abuse potential, no dependence<\/strong><\/p>\n

Buspirone is a Schedule-uncontrolled medication in all major regulatory zones. It produces no euphoria, no tolerance, no withdrawal, and is well-suited to patients with substance-use history or those who must avoid impairment (drivers, pilots, machine operators, surgeons).<\/p>\n<\/div>\n

Veelvoorkomende bijwerkingen<\/h2>\n